8-K filing — IRIDEX CORP (IRIX)
Filed: 2026-09-02 AccNo: 0001193125-26-380229 Size: 173 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Iridex Expands Its EyeProGPO Product Offering To Include The Company’s Line Of EndoProbe Handpieces
Through the agreement, more than 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Handpieces, expanding the value Iridex provides to ophthalmology practices, ambulatory surgery centers,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Iridex shares are trading lower after the company reported worse-than-expected Q2 financial results.
Full Transcript: Iridex Q2 2026 Earnings Call
Iridex (NASDAQ:IRIX) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data.
Iridex Affirms FY2026 Sales Guidance of $51.000M-$53.000M vs $53.227M Est
Iridex (NASDAQ:IRIX) affirms FY2026 sales outlook from $51.000 million-$53.000 million to $51.000 million-$53.000 million vs $53.227 million estimate.